HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SKB BIO-B

514.500

-9.000-1.72%

Volume:147.60K

Turnover:76.48M

Market Cap:119.97B

PE:-390.94

High:534.000

Open:530.000

Low:510.000

Close:523.500

52wk High:541.500

52wk Low:152.000

Shares:233.19M

HK Float Shares:162.77M

Volume Ratio:0.48

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.316

ROE:-17.56%

ROA:-10.17%

PB:21.88

PE(LYR):-390.94

PS:73.11

Loading ...

Overview Company News Filings

Sichuan Kelun-Biotech's Core Product Sacituzumab Tirumotecan and Tagitanlimab Combination Receives Breakthrough Therapy Designation for First-Line Treatment of Metastatic Non-Squamous NSCLC by China's NMPA

Sichuan Kelun-Biotech Announces Promising Phase 1/2 Study Results for TROP2 ADC Sacituzumab Tirumotecan in Advanced Solid Tumors

Sichuan Kelun-Biotech Secures First Global Approval for Sacituzumab Tirumotecan in Treating Advanced EGFR-Mutant NSCLC

Sichuan Kelun-Biotech Raises $250 Million Through Oversubscribed Share Placement to Boost R&D and Expand Product Pipeline

BUZZ-Sichuan Kelun-Biotech falls most in 4 weeks on discounted share sale

Sichuan Kelun-Biotech Announces New Shareholder Agreement for Placing of H Shares

BRIEF-Accelerated Bookbuild Offering Of H Shares In Sichuan Kelun-Biotech Biopharmaceutical, Term Sheet Shows

SKB Biopharmaceutical Gets Upfront Payment Under Drug License Contract

MT Newswires Live

Sichuan Kelun-Biotech Announces Phase 2 Clinical Trial for Novel Asthma and COPD Treatment SKB378/HBM9378/WIN378

Sichuan Kelun-Biotech Unveils Promising Results from Six Innovative Drug Studies at 2025 ASCO Annual Meeting

Chinese Regulator Accepts SKB Biopharma's New Indication Application for Breast Cancer Drug

MT Newswires Live

Sichuan Kelun-Biotech's Fourth NDA for Sac-TMT Accepted for Priority Review by China's CDE for Advanced HR+/HER2- Breast Cancer Treatment

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical New Indication Application For Sac-Tmt Accepted By NMPA

Sichuan Kelun-Biotech Announces Acceptance of New Indication Application for Sacituzumab Tirumotecan by National Medical Products Administration

Kelun-Biotech Repurchases Certificate of Deposit from Tongwei for 53 Million Yuan

MT Newswires Live

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Acquired Large- Denomination Negotiable Certificate Of Deposit

Sichuan Kelun-Biotech Completes Share Conversion, Boosting H Shares by 25 Million

SKB Biopharmaceutical Gets US FDA Clinical Trial Clearance for Anti-Tumor Drug; Shares Jump 6%

MT Newswires Live

BRIEF-Kelun-Biotech's Novel ADC Drug SKB518 Has Been Granted The Clearance Of IND From The United States Food And Drug Administration (FDA)

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Syas New Drug Clearance For Adc Drug Skb518

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/06990/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"SKB BIO-B","latestPrice":514.5,"timestamp":1757476507074,"preClose":523.5,"halted":0,"volume":147600,"delay":0,"floatShares":162769979,"shares":233185969,"eps":-1.316060508270384,"marketStatus":"Trading","change":-9,"latestTime":"09-10 11:56:50","open":530,"high":534,"low":510,"amount":76475200,"amplitude":0.045845,"askPrice":515.5,"askSize":1300,"bidPrice":514,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.50144599088856,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1757476800000},"marketStatusCode":2,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":523.5,"openAndCloseTimeList":[[1757467800000,1757476800000],[1757480400000,1757491200000]],"volumeRatio":0.48152,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":162769979,"roa":"-10.17%","roe":"-17.56%","lyrEps":-1.316061,"volumeRatio":0.48152,"shares":233185969,"dividePrice":0,"high":534,"amplitude":0.045845,"preClose":523.5,"low":510,"week52Low":152,"pbRate":"21.88","psRate":"73.11","week52High":541.5,"institutionHeld":0,"latestPrice":514.5,"committee":-0.857143,"eps":-1.316060508270384,"divideRate":0,"volume":147600,"delay":0,"ttmEps":-3.50144599088856,"open":530,"prevYearClose":163.3,"prevWeekClose":524,"prevMonthClose":454.2,"prevQuarterClose":327.2,"fiveDayClose":513.5,"twentyDayClose":418.4,"sixtyDayClose":331.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-08-18","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755480600000,"name":null,"time":"","dateTimestamp":1755446400000,"actualEps":null},{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"Post Market","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"Post Market","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3158,"buy":0.5789,"hold":0.1053,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5789,"analysts":19,"updateTime":1755705600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-09-08","current":-152.440449,"percent":0.362617,"low":-351.800852,"twenty":-215.669071,"median":-80.439464,"eighty":-47.451486,"high":-21.029201,"avg":-125.589374,"sd":85.421153,"marketCap":120328299643},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200},{"date":"2025-04-25","current":-235.137362,"twenty":-160.624501,"median":-68.953584,"eighty":-45.131919,"marketCap":66771338400},{"date":"2025-05-02","current":-274.570331,"twenty":-161.195254,"median":-69.468586,"eighty":-45.197413,"marketCap":78134738400},{"date":"2025-05-09","current":-249.374354,"twenty":-161.514906,"median":-70.050704,"eighty":-45.202208,"marketCap":71462875059},{"date":"2025-05-16","current":-247.507619,"twenty":-162.87029,"median":-70.732965,"eighty":-45.217068,"marketCap":71507400214},{"date":"2025-05-23","current":-244.618313,"twenty":-163.824551,"median":-71.32983,"eighty":-45.58151,"marketCap":70884048033},{"date":"2025-05-30","current":-244.159494,"twenty":-165.025774,"median":-71.669987,"eighty":-45.601984,"marketCap":71062148656},{"date":"2025-06-06","current":-258.187076,"twenty":-166.004403,"median":-72.203519,"eighty":-46.006494,"marketCap":75336563613},{"date":"2025-06-13","current":-271.678883,"twenty":-167.701589,"median":-72.488214,"eighty":-46.133909,"marketCap":79304691313},{"date":"2025-06-20","current":-252.757485,"twenty":-168.349452,"median":-72.789206,"eighty":-46.315126,"marketCap":73636805593},{"date":"2025-06-27","current":-255.806605,"twenty":-169.647858,"median":-73.569836,"eighty":-46.457129,"marketCap":74733815733},{"date":"2025-07-04","current":-283.173205,"twenty":-171.495185,"median":-73.869687,"eighty":-46.685504,"marketCap":82732847998},{"date":"2025-07-11","current":-266.231967,"twenty":-173.142078,"median":-74.539848,"eighty":-46.749361,"marketCap":77704884860},{"date":"2025-07-18","current":-304.526119,"twenty":-187.755426,"median":-75.01675,"eighty":-46.798833,"marketCap":88812112519},{"date":"2025-07-25","current":-289.211949,"twenty":-196.095673,"median":-75.38559,"eighty":-46.877904,"marketCap":84652615741},{"date":"2025-08-01","current":-318.351212,"twenty":-209.071662,"median":-75.715906,"eighty":-46.908544,"marketCap":92605939250},{"date":"2025-08-08","current":-315.832709,"twenty":-214.487876,"median":-76.34536,"eighty":-47.149906,"marketCap":92103142937},{"date":"2025-08-15","current":-340.637946,"twenty":-221.73884,"median":-77.157567,"eighty":-47.354138,"marketCap":99188000086},{"date":"2025-08-22","current":-135.707825,"twenty":-221.73884,"median":-78.335478,"eighty":-47.421279,"marketCap":106638527281},{"date":"2025-08-29","current":-131.473703,"twenty":-217.466422,"median":-78.819337,"eighty":-47.438439,"marketCap":103804584421},{"date":"2025-09-05","current":-151.82862,"twenty":-215.82299,"median":-80.340969,"eighty":-47.449348,"marketCap":119756940196},{"date":"2025-09-08","current":-152.440449,"twenty":-215.669071,"median":-80.439464,"eighty":-47.451486,"marketCap":120328299643}],"updateTime":1757435858293},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542325795","title":"Sichuan Kelun-Biotech's Core Product Sacituzumab Tirumotecan and Tagitanlimab Combination Receives Breakthrough Therapy Designation for First-Line Treatment of Metastatic Non-Squamous NSCLC by China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2542325795","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542325795?lang=en_us&edition=fundamental","pubTime":"2025-06-11 07:41","pubTimestamp":1749598882,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech's Core Product Sacituzumab Tirumotecan and Tagitanlimab Combination Receives Breakthrough Therapy Designation for First-Line Treatment of Metastatic Non-Squamous NSCLC by China's NMPA. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced that its core product, the TROP2-directed antibody-drug conjugate  sacituzumab tirumotecan , in combination with the PD-L1 monoclonal antibody  tagitanlimab, has been granted Breakthrough Therapy Designation by the National Medical Products Administration in China. This designation is specifically for the first-line treatment of locally advanced, metastatic non-squamous non-small cell lung cancer  without actionable genomic alterations. This development marks a significant milestone for the company as it continues to advance its clinical research program, which includes multiple ongoing studies in collaboration with global partners.Disclaimer: This news brief was created by Public Technologies  using generative artifici","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL5fJZVs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU1934453819.USD","BK0060","LU1064131003.USD","LU1979443071.USD","06990","LU2148510915.USD","BK1161","LU0196878994.USD","002422","LU1064130708.USD"],"gpt_icon":0},{"id":"2542466553","title":"Sichuan Kelun-Biotech Announces Promising Phase 1/2 Study Results for TROP2 ADC Sacituzumab Tirumotecan in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2542466553","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542466553?lang=en_us&edition=fundamental","pubTime":"2025-06-10 23:49","pubTimestamp":1749570564,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Announces Promising Phase 1/2 Study Results for TROP2 ADC Sacituzumab Tirumotecan in Advanced Solid Tumors. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire  on June 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL1LNprl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU0196878994.USD","06990","LU1979443071.USD","LU1064131003.USD","LU1934453819.USD","BK0060","LU1064130708.USD","LU2148510915.USD","002422","BK1161"],"gpt_icon":0},{"id":"2541897790","title":"Sichuan Kelun-Biotech Secures First Global Approval for Sacituzumab Tirumotecan in Treating Advanced EGFR-Mutant NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2541897790","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541897790?lang=en_us&edition=fundamental","pubTime":"2025-06-07 11:04","pubTimestamp":1749265493,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a leading biopharmaceutical company, has announced the approval of sacituzumab tirumotecan  by the National Medical Products Administration  for the treatment of adult patients with epidermal growth factor receptor  mutant-positive locally advanced or metastatic non-squamous non-small cell lung cancer . This approval follows the progression on EGFR-tyrosine kinase inhibitor therapy and platinum-based chemotherapy. The approval, granted in March 2025, marks the first global sanctioning of a TROP2 antibody-drug conjugate for a lung cancer indication. The decision was based on encouraging data from the OptiTROP-Lung03 study, demonstrating significant survival benefits and a manageable safety profile of sac-TMT, which could potentially establish it as a new standard of care for this patient population.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250607:nNDL9vRJ2s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1979443071.USD","BK1161","LU1064130708.USD","LU1064131003.USD","LU0196878994.USD","06990","BK0239","LU2148510915.USD","BK0060","LU1934453819.USD","002422"],"gpt_icon":0},{"id":"2541886163","title":"Sichuan Kelun-Biotech Raises $250 Million Through Oversubscribed Share Placement to Boost R&D and Expand Product Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2541886163","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541886163?lang=en_us&edition=fundamental","pubTime":"2025-06-06 10:53","pubTimestamp":1749178430,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced a successful placement of 5,918,000 H shares, raising approximately US$250 million. The shares were issued at HK$331.8 each and represented about 2.54% of the company's expanded share capital. The offering attracted strong interest from investors, being multiple times oversubscribed, with participation from global long-only funds, sovereign wealth funds, and healthcare specialist funds. This placement, the largest in the Hong Kong biopharma sector over the past year, will support the company's pipeline strategy and accelerate global clinical development, aiming to deliver innovative cancer treatments. The funds will be used for research and development, clinical trials, and enhancing internal and external technological capabilities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL2DZr2P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","BK0239","002422","LU1064130708.USD","LU1934453819.USD","LU1979443071.USD","BK1161","LU2148510915.USD","LU0196878994.USD","06990","BK0060"],"gpt_icon":0},{"id":"2541012954","title":"BUZZ-Sichuan Kelun-Biotech falls most in 4 weeks on discounted share sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2541012954","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541012954?lang=en_us&edition=fundamental","pubTime":"2025-06-05 11:39","pubTimestamp":1749094790,"startTime":"0","endTime":"0","summary":"BUZZ-Sichuan Kelun-Biotech falls most in 4 weeks on discounted share sale ** Shares of Sichuan Kelun-Biotech Biopharmaceutical 6990.HK fall 6.4% to HK$336, on course for the biggest one-day drop since May 7** Stock  on track to snap two straight sessions of gains** The oncology-focused drug developer plans sale of 5.92 mln new shares, or 2.5% of the enlarged share capital, in share placement raising HK$1.96 bln  for R&D, products commercialization and expanding product pipeline portfolio** The new shares will be issued at HK$331.8 apiece, or  7.6% discount to Wednesday's close of HK$359 each ** Hang Seng Biotech Index .HSHKBIO slips 0.7%, while Hang Seng Index .HSI climbs 0.7%** YTD, stock up 107.6%    ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nL2N3S8034:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU1064131003.USD","BK0060","LU2148510915.USD","LU0196878994.USD","002422","LU1979443071.USD","06990","BK1161","LU1064130708.USD","LU1934453819.USD"],"gpt_icon":0},{"id":"2541097258","title":"Sichuan Kelun-Biotech Announces New Shareholder Agreement for Placing of H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2541097258","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541097258?lang=en_us&edition=fundamental","pubTime":"2025-06-05 07:54","pubTimestamp":1749081261,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced a new shareholder agreement involving the placement of new H shares under a general mandate. The agreement, which was entered into on June 5, 2025, involves Goldman Sachs and Citigroup as the overall coordinators and placing agents. This placement is part of a strategic move to raise capital, with the new shares to be listed on the Hong Kong Stock Exchange under stock code 6990. The company has clarified that there are no intentions to register these securities under the U.S. Securities Act or conduct a public offering in the United States. Additionally, proposed amendments to the articles of association have been announced.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. S","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL8J7yJ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836914.USD","LU2237443978.SGD","LU2125154778.USD","LU2471134523.USD","LU2471134796.USD","IE00B19Z3B42.SGD","LU1979443071.USD","BK4534","IE0004086264.USD","LU0048573561.USD","LU0648001328.SGD","BK0239","LU2237443895.HKD","LU0061475181.USD","LU0742534661.SGD","IE0002270589.USD","LU1267930227.SGD","LU0251142724.SGD","LU0320765646.SGD","BK4566","06990","LU0130517989.USD","LU2456880835.USD","LU1868836757.USD","LU2750360641.GBP","BK4588","LU0251131958.USD","LU2236285917.USD","LU0106831901.USD","LU0196878994.USD","LU1201861249.SGD","BK4552","BK4550","BK0060","LU1894683264.USD","BK1161","LU2360032135.SGD","LU1868837300.USD","BK4559","LU0098860793.USD","LU1894683348.USD","BK4585","LU2148510915.USD","LU2237443549.SGD","002422","IE0034235188.USD","LU1791807156.HKD","LU0170899867.USD","LU1868837136.USD","LU2471134952.CNY"],"gpt_icon":0},{"id":"2540057513","title":"BRIEF-Accelerated Bookbuild Offering Of H Shares In Sichuan Kelun-Biotech Biopharmaceutical, Term Sheet Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2540057513","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540057513?lang=en_us&edition=fundamental","pubTime":"2025-06-04 18:28","pubTimestamp":1749032889,"startTime":"0","endTime":"0","summary":"BRIEF-Accelerated Bookbuild Offering Of H Shares In Sichuan Kelun-Biotech Biopharmaceutical, Term Sheet ShowsJune 4  - ACCELERATED BOOKBUILD OFFERING OF H SHARES IN SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL - TERM SHEETOFFERING SIZE OF US$200 MILLION UNDER ISSUANCE OF H SHARES - TERM SHEETPRICE RANGE SET AT HK$330.20 – 341.00 FOR H SHARES OFFERING - TERM SHEETFurther company coverage: 6990.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S7073:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2537133891","title":"SKB Biopharmaceutical Gets Upfront Payment Under Drug License Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2537133891","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537133891?lang=en_us&edition=fundamental","pubTime":"2025-05-23 19:00","pubTimestamp":1747998001,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  received an upfront payment from Windward Bio under a license agreement for an anti-thymic stromal lymphopoietin monoclonal antibody , a Friday Hong Kong bourse filing said.The payment includes cash received in February and equity interest in the parent company of Windward Bio, which was settled in May.The biopharmaceutical firm and HBM  in January granted Switzerland-based Windward Bio an exclusive license for the research, development, manufacturing, and commercialization of the drug across the globe, except in Greater China and several Southeast and West Asian countries.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06990","BK1161","BK1574","02142","BK1583","LU0196878994.USD"],"gpt_icon":0},{"id":"2537185606","title":"Sichuan Kelun-Biotech Announces Phase 2 Clinical Trial for Novel Asthma and COPD Treatment SKB378/HBM9378/WIN378","url":"https://stock-news.laohu8.com/highlight/detail?id=2537185606","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537185606?lang=en_us&edition=fundamental","pubTime":"2025-05-23 16:40","pubTimestamp":1747989604,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL3gFccW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK0239","LU1934453819.USD","BK0060","BK1161","LU1064130708.USD","06990","002422","LU1064131003.USD","LU2148510915.USD","LU1979443071.USD"],"gpt_icon":0},{"id":"2537973751","title":"Sichuan Kelun-Biotech Unveils Promising Results from Six Innovative Drug Studies at 2025 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2537973751","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537973751?lang=en_us&edition=fundamental","pubTime":"2025-05-23 07:37","pubTimestamp":1747957069,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the results of six clinical studies that will be presented at the 2025 American Society of Clinical Oncology  Annual Meeting in Chicago. The company will showcase data from its innovative drugs, including the TROP2 antibody-drug conjugate sacituzumab tirumotecan , the PD-L1 monoclonal antibody tagitanlimab, and the RET inhibitor KL590586 . These studies cover various treatments, such as sac-TMT in patients with previously treated advanced EGFR-mutated non-small-cell lung cancer . The company cautions that sacituzumab tirumotecan, tagitanlimab, and A400 may not ultimately be successfully developed and commercialized.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Ke","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL8qWCzT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","002422","06990","BK0239","BK0060","LU0196878994.USD","LU2148510915.USD","LU1979443071.USD","LU1934453819.USD","LU1064130708.USD","BK1161"],"gpt_icon":0},{"id":"2537994036","title":"Chinese Regulator Accepts SKB Biopharma's New Indication Application for Breast Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2537994036","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537994036?lang=en_us&edition=fundamental","pubTime":"2025-05-22 15:27","pubTimestamp":1747898878,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990) new indication application for sacituzumab tirumotecan was accepted by China's National Medical Products Administration, a Thursday Hong Kong bourse filing said.The new indication is for the treatment of adult patients with breast cancer.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2537969482","title":"Sichuan Kelun-Biotech's Fourth NDA for Sac-TMT Accepted for Priority Review by China's CDE for Advanced HR+/HER2- Breast Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2537969482","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537969482?lang=en_us&edition=fundamental","pubTime":"2025-05-22 09:58","pubTimestamp":1747879090,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech's Fourth NDA for Sac-TMT Accepted for Priority Review by China's CDE for Advanced HR+/HER2- Breast Cancer Treatment. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire  on May 22, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL3BHCW3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK0060","BK1161","LU2148510915.USD","LU1064131003.USD","LU0196878994.USD","LU1979443071.USD","BK0239","002422","LU1934453819.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2537650079","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical New Indication Application For Sac-Tmt Accepted By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2537650079","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537650079?lang=en_us&edition=fundamental","pubTime":"2025-05-22 09:24","pubTimestamp":1747877061,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical New Indication Application For Sac-Tmt Accepted By NMPAMay 22  - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:NEW INDICATION APPLICATION FOR SACITUZUMAB TIRUMOTECAN  ACCEPTED BY NMPAFurther company coverage: 6990.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nFWN3RT3HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2537950464","title":"Sichuan Kelun-Biotech Announces Acceptance of New Indication Application for Sacituzumab Tirumotecan by National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2537950464","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537950464?lang=en_us&edition=fundamental","pubTime":"2025-05-22 07:49","pubTimestamp":1747871377,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Announces Acceptance of New Indication Application for Sacituzumab Tirumotecan by National Medical Products Administration. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on May 22, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL3vxCSt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","002422","06990","BK0239","BK0060","LU0196878994.USD","LU2148510915.USD","LU1979443071.USD","LU1934453819.USD","LU1064130708.USD","BK1161"],"gpt_icon":0},{"id":"2534171227","title":"Kelun-Biotech Repurchases Certificate of Deposit from Tongwei for 53 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2534171227","media":"MT Newswires Live","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534171227?lang=en_us&edition=fundamental","pubTime":"2025-05-09 17:37","pubTimestamp":1746783467,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical , or Kelun-Biotech, reacquired a negotiable certificate of deposit from Tongwei  for 53 million yuan, according to a Thursday filing with the Hong Kong bourse.The large-denomination certificate of deposit had a principal amount of 50 million yuan and was first issued to Kelun-Biotech by Industrial Bank  in May 2024. It was then sold to Tongwei in March by the company, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0224","LU0196878994.USD","BK0015","LU1048596156.SGD","600438","LU1781817850.SGD","LU1580142542.USD","BK0077","LU1328615791.USD","BK0054","BK0044","BK0196","LU0572940350.SGD","BK0028","BK1161","LU0572939691.SGD","06990","LU1655091616.SGD","BK0278","BK0012","BK0183","LU0264606111.USD","BK0188","BK0238","601166","LU0821914370.USD","BK0187"],"gpt_icon":0},{"id":"2533132078","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Acquired Large- Denomination Negotiable Certificate Of Deposit","url":"https://stock-news.laohu8.com/highlight/detail?id=2533132078","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533132078?lang=en_us&edition=fundamental","pubTime":"2025-05-08 22:56","pubTimestamp":1746716163,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Acquired Large- Denomination Negotiable Certificate Of DepositMay 8  - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:ACQUIRED FROM TONGWEI INDUSTRIAL BANK LARGE- DENOMINATION NEGOTIABLE CERTIFICATE OF DEPOSIT FOR RMB53 MILLIONFurther company coverage: 6990.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG37F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2533514155","title":"Sichuan Kelun-Biotech Completes Share Conversion, Boosting H Shares by 25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2533514155","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533514155?lang=en_us&edition=fundamental","pubTime":"2025-05-06 09:39","pubTimestamp":1746495559,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced a conversion of 25,421,196 domestic shares into H shares, as noted in their recent submission to the Hong Kong Exchanges and Clearing Limited. This change increases the company's H shares listed on the exchange, reflecting a strategic adjustment in their share structure. The modification took effect on April 25, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on May 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nNDL44H1pb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","LU2148510915.USD","BK1161","06990","LU1064130708.USD","LU0196878994.USD","002422","BK0239","BK0060"],"gpt_icon":0},{"id":"2529390191","title":"SKB Biopharmaceutical Gets US FDA Clinical Trial Clearance for Anti-Tumor Drug; Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529390191","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529390191?lang=en_us&edition=fundamental","pubTime":"2025-04-22 12:27","pubTimestamp":1745296053,"startTime":"0","endTime":"0","summary":"The US Food and Drug Administration granted Sichuan Kelun-Biotech Biopharmaceutical  an investigational new drug clearance for its SKB518 drug, according to a Monday filing with the Hong Kong bourse.The clearance will allow the company to begin clinical studies in the US, the filing said.SKB518 is indicated for advanced solid tumors, the filing said.Shares in the drug company rose 6% during late morning trading on Tuesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2529808136","title":"BRIEF-Kelun-Biotech's Novel ADC Drug SKB518 Has Been Granted The Clearance Of IND From The United States Food And Drug Administration (FDA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529808136","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529808136?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:02","pubTimestamp":1745236927,"startTime":"0","endTime":"0","summary":"BRIEF-Kelun-Biotech's Novel ADC Drug SKB518 Has Been Granted The Clearance Of IND From The United States Food And Drug Administration (FDA)April 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA9YZQMK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2529768978","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Syas New Drug Clearance For Adc Drug Skb518","url":"https://stock-news.laohu8.com/highlight/detail?id=2529768978","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529768978?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:12","pubTimestamp":1745230356,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Syas New Drug Clearance For Adc Drug Skb518April 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical 6990.HK:INVESTIGATIONAL NEW DRUG CLEARANCE FOR INN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nFWN3QX00X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":44,"code":"91000000","status":"200"}]}}